Provided by Tiger Fintech (Singapore) Pte. Ltd.

Moleculin Biotech

0.6700
-0.0201-2.91%
Post-market: 0.67490.0049+0.73%19:49 EDT
Volume:786.51K
Turnover:527.72K
Market Cap:9.47M
PE:-0.15
High:0.7163
Open:0.6510
Low:0.6270
Close:0.6901
Loading ...

Moleculin Announces World Health Organization Approval of “Naxtarubicin” as International Non-Proprietary Name for Annamycin

THOMSON REUTERS
·
06 May

BRIEF-Moleculin Biotech Granted Two Additional U.S. Patents For Annamycin

Reuters
·
05 May

Moleculin Biotech Inc - Granted Two Additional U.S. Patents for Annamycin

THOMSON REUTERS
·
05 May

Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

GlobeNewswire
·
05 May

BRIEF-Moleculin Announces New Pre-Clinical Data For Annamycin

Reuters
·
29 Apr

Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer

THOMSON REUTERS
·
29 Apr

Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer

GlobeNewswire
·
29 Apr

Moleculin Biotech Releases Corporate Presentation Online

TIPRANKS
·
22 Apr

Moleculin Biotech’s Annamycin Highlighted at AACR 2025

TIPRANKS
·
17 Apr

BRIEF-Moleculin Announces Acceptance Of Abstract To Be Presented At The American Association For Cancer Research Annual Meeting 2025

Reuters
·
17 Apr

Moleculin Announces Acceptance of Abstract to Be Presented at the American Association for Cancer Research (Aacr) Annual Meeting 2025

THOMSON REUTERS
·
17 Apr

Moleculin Biotech doses first patient in Phase 3 MIRACLE trial

TipRanks
·
02 Apr

BRIEF-Moleculin Doses First Patient In Pivotal, Adaptive Phase 3 Miracle Trial

Reuters
·
01 Apr

Moleculin Biotech Inc - Preliminary Data From First 45 Subjects Expected in H2 2025

THOMSON REUTERS
·
01 Apr

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 Miracle Trial

THOMSON REUTERS
·
01 Apr

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

GlobeNewswire
·
01 Apr

All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy

Zacks
·
27 Mar

Moleculin Biotech Raised to Buy From Hold by Maxim Group

Dow Jones
·
25 Mar

Maxim Upgrades Moleculin Biotech to Buy From Hold, Price Target is $4

MT Newswires Live
·
25 Mar

Moleculin Biotech Inc : Maxim Group Raises to Buy From Hold

THOMSON REUTERS
·
25 Mar